Company Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications.
In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson’s disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders.
Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
| Country | United States |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 610 |
| CEO | Dr. Sharon Mates Ph.D. |
Contact Details
Address: 430 East 29th Street New York, New York 10016 United States | |
| Phone | 212-923-3344 |
| Website | intracellulartherapies.com |
Stock Details
| Ticker Symbol | ITCI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001567514 |
| CUSIP Number | 46116X101 |
| ISIN Number | US46116X1019 |
| Employer ID | 36-4742850 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sharon Mates Ph.D. | Co-Founder, Chairman and Chief Executive Officer |
| Michael I. Halstead J.D. | President |
| Dr. Suresh K. Durgam M.D. | Executive Vice President and Chief Medical Officer |
| Mark Neumann | Executive Vice President and Chief Commercial Officer |
| Dr. Robert E. Davis Ph.D. | Senior Vice President and Chief Scientific Officer |
| Juan Fernando Sanchez | Vice President of Corporate Communications and Investor Relations |
| Karen Patruno Sheehy Esq. | Senior Vice President and Chief Compliance Officer |
| Dr. Michael Olchaskey | Senior Vice President and Head of Regulatory Affairs |
| John A. Bardi | Senior Vice President of Market Access, Policy and Government Affairs |
| Dr. Willie R. Earley M.D. | Senior Vice President and Head of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 25, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 18, 2024 | 8-K | Current Report |
| Jun 18, 2024 | 144 | Filing |
| Jun 18, 2024 | 8-K | Current Report |
| May 7, 2024 | 10-Q | Quarterly Report |
| May 7, 2024 | 8-K | Current Report |
| Apr 29, 2024 | ARS | Filing |
| Apr 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 24, 2024 | 8-K | Current Report |